ScholarIQanswers from OpenAlex & ORCID
Joaquín Martínez‐López
ResearcherPublications, citations & collaboration network
Joaquín Martínez‐López is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Joaquín Martínez‐López have?
ScholarIQindexed works
Joaquín Martínez‐López has 1,556 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Joaquín Martínez‐López have?
ScholarIQcitation count
Joaquín Martínez‐López has 26,719 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Joaquín Martínez‐López?
ScholarIQh-index
Joaquín Martínez‐López has an h-index of 72 in OpenAlex.
What is the i10-index of Joaquín Martínez‐López?
ScholarIQi10-index
Joaquín Martínez‐López has an i10-index of 399 in OpenAlex.
What is the ORCID of Joaquín Martínez‐López?
ScholarIQorcid
The ORCID for Joaquín Martínez‐López is on the source record.
What is the OpenAlex record for Joaquín Martínez‐López?
ScholarIQopenalex
The OpenAlex for Joaquín Martínez‐López is on the source record.
What are the most-cited papers on Joaquín Martínez‐López?
ScholarIQmost cited works
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesús F. San Miguel, Albert Oriol, Ajay K. Nooka, Thomas G. Martin, Laura Rosiñol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, María‐Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Surbhi Sidana, Michel Delforge, Lixia Pei, Danielle Trancucci, Raluca Verona, Suzette Girgis, Shun Xin Wang Lin, Yunsi Olyslager, Mindy Jaffe, Clarissa Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saußele, Johan Richter, Joëlle Guilhot, Franz Gruber, Henrik Hjorth-Hansen, António Almeida, Jeroen J. W. M. Janssen, Jiřı́ Mayer, Perttu Koskenvesa, Panayiotis Panayiotidis, Ulla Olsson‐Strömberg, Joaquín Martínez‐López, Philippe Rousselot, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Kateřina Machová Poláková, Martin C. Müller, Satu Mustjoki, Marc Berger, Alice Fabarius, Wolf‐Karsten Hofmann, Andreas Hochhaus, Markus Pfirrmann, François‐Xavier Mahon, Gert J. Ossenkoppele, Maria Pagoni, Stina Söderlund, Martine Escoffre‐Barbe, Gabriel Étienne, Jolanta Dengler, Françoise Huguet, Nikolas von Bubnoff, Hana Klamová, Edgar Faber, François Guilhot, Kourosh Lotfi, Delphine Réa, Tim H. Brümmendorf, G.E. de Greef, Leif Stenke, Franck E. Nicolini, Laurence Legros, Andreas Burchert, J Voglová, Aude Charbonnier, Emmanuel Gyan, Volker Kunzmann, Peter E. Westerweel
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf, Nizar J. Bahlis, H. Miles Prince, Rubén Niesvizky, Paula Rodríguez‐Otero, Joaquín Martínez‐López, Guenther Koehne, Cyrille Touzeau, Yogesh Jethava, Hang Quach, Julien Depaus, Hisayuki Yokoyama, Afshin Eli Gabayan, Don A. Stevens, Ajay K. Nooka, Salomon Manier, Noopur Raje, Shinsuke Iida, Marc S. Raab, Emma Searle, Eric Leip, Sharon T. Sullivan, Umberto Conte, Mohamed Elmeliegy, Akos Czibere, Andrea Viqueira, Mohamad Mohty